BRITANNIA TO DEVELOP NASAL POWDER FOR MIGRAINE SUFFERERS.Britannia Pharmaceuticals, London, U.K., plans to begin a clinical study on its nasal powder dihydroergotamine (DHE DHE Dihydroergotamine (anti-migraine drug) DHE Design Human Engineering DHE Dependable Highway Express (Los Angeles, CA) DHE dihematoporphyrin ether DHE Dehacked (Doom game utility) ) product for the treatment of migraines before the end of the year. This new initiative further expands upon the company's proprietary expertise in nasal powder drug delivery, which includes developing treatments for late-stage Parkinson's disease Parkinson's disease or Parkinsonism, degenerative brain disorder first described by the English surgeon James Parkinson in 1817. When there is no known cause, the disease usually appears after age 40 and is referred to as Parkinson's disease. and erectile dysfunction Erectile Dysfunction Definition Erectile dysfunction (ED), formerly known as impotence, is the inability to achieve or maintain an erection long enough to engage in sexual intercourse. . With DHE nasal powder, Britannia aims to offer a migraine treatment that not only works very quickly, but also for a longer time than most migraine treatments, helping prevent the common problem of migraines recurring. Historically, many pharmaceutical and biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. have avoided developing powders for nasal drug delivery because there is a perception that they can be irritating. Britannia has created a formula that is non-irritating, fast-acting, as bioavailable as subcutaneous injections and more stable than nasal liquid formulations. "We are very enthusiastic about the potential for DHE nasal powder to make a significant difference in the lives of millions of migraine sufferers worldwide," said Max Noble, managing director of Britannia. "This product will provide relief from migraine pain very quickly and for longer than most medications -- huge benefits to those who are forced to miss days of work and life events because of their pain." Migraine headaches have been called the most common neurological condition in the world and it is estimated that up to 20% of the world's population suffer from migraines. The World Health Organization recently recognized migraines among the world's top 20 leading causes of disability. In the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. , according to the National Institute of Neurological Disorders and Stroke The National Institute of Neurological Disorders and Stroke is a part of the U.S. National Institutes of Health. The NINDS conducts and supports research on brain and nervous system disorders. Created by the U.S. and National Headache Foundations, migraine headaches affect nearly 30 million Americans, disturbing 1 in 4 households, causing 157 million missed days of work, and costing American taxpayers $13 billion in missed work or reduced productivity each year. In the United Kingdom, the Migraine Action Association Migraine Action Association is a British medical research charity dedicated to the curing of migraine. MAA was founded in 1958. See also
In addition to DHE nasal powder for migraines and nasal powders for the treatment of Parkinson's disease and erectile dysfunction, Britannia has also developed a dry powder Dry Powder A slang term for cash reserves kept on hand to cover future obligations. Notes: For example, if a venture capitalist expects bad times in the IPO markets you might hear him say something like, "we want to keep enough dry powder around to keep funding our delivered via aerosol to prevent surgical adhesions and a respiratory powder for the treatment of asthma and other respiratory diseases. About Britannia Pharmaceuticals Founded in 1981 Britannia Pharmaceuticals Limited is a United Kingdom-based pharmaceutical firm whose mission is to become a leading supplier of innovative products for niche medical conditions. The company has pioneered new treatments for some of the world's most debilitating de·bil·i·tat·ing adj. Causing a loss of strength or energy. Debilitating Weakening, or reducing the strength of. Mentioned in: Stress Reduction conditions including asthma, Parkinson's disease, drug addiction, erectile dysfunction and surgical adhesions. In addition to these treatments, Britannia has also developed nasal and respiratory drug delivery technologies that are applicable to a wide range of treatments. Britannia is a Forum Bioscience Company. For more information, visit http://www.britannia-pharm.co.uk or call 617/443-9933, ext. 329. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion